A non-invasive, fast on/off "Odourgenetic" Method to Manipulate Physiology

Yanqiong Wu[1][†], Shanchun Su[1][†], Xueqin Xu[1][†], Xincai Hao[2], Wei Lu[2], Xiaohui Li[1], Linhan Wang[1],

Wei Tian[1], Yan Gao[1], Gang Cao[3,4*], Changbin Ke[1*]

[1]Institute of Anesthesiology & Pain (IAP), Department of Anesthesiology, Taihe Hospital, Hubei

University of Medicine, Shiyan, Hubei, China

[2]College of Pharmacy, Hubei University of Medicine, Shiyan, Hubei, China

[3]State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan,

430070, China

[4]College of Veterinary Medicine / College of Bio-Medicine and Health, Huazhong Agricultural
University, Wuhan, China.
13

Corresponding authors

[*]Gang Cao (gcao@mail.hzau.edu.cn) and Chanbin Ke (changbinke-iap@taihehospital.com)

[†] The following authors contributed equally: Yanqiong Wu,Shanchun Su and Xueqin Xu.

Summary

Manipulating molecular processes governing physiological functions has significant

potential for clinical therapeutics and is an important approach to elucidate the cellular basis

of physiological functions. Here, we designed a Odourgenetic system co-expressed *Drosophila*

odorant receptor system (DORs) consisting of OR35a and OR83b, which were exclusively

activated by their odor ligand, 2-pentanone. Applying 2-pentanone to DOR-expressing cells

or tissues induced calcium influx and membrane depolarization. By inhalation of 2-

pentanone, we successfully applied DORs to manipulate behaviour, control insulin secretion

and regulate blood glucose and manipulate muscle contraction and associated limb

movement. Because 2-pentanone rapidly enters the blood upon inhalation and leaves the

body by exhalation, this odorant can be used with DORs to manipulate cellular function, and

the manipulation can be terminated at any time. Such feature approach significantly

improves the safety and controllability of DORs used in the clinic. Thus, the present study

developed a non-invasive, controllable, fast on/off method to manipulate cellular activity and

behaviour on a time scale of minutes.

Developing a rapid, controllable method for manipulating physiological functions has significant

potential for clinical therapeutics and basic research. Optogenetics has provided optical control of

neuronal activity at the millisecond time scale[1-5]. However, this approach requires direct optical

access to brain tissue, which is difficult because blue light does not readily penetrate whole

organisms; light must be delivered using costly specialized equipment such as custom blue light

sources with fibre optics or two-photon illumination systems[6]. Additionally, given the need for

invasive equipment implantation and sufficient power[7], it is difficult to apply optogenetics for

disease treatment in real clinical practice.

Chemogenetic designer receptors exclusively activated by designer drugs (DREADDs)[8] are a

powerful approach for remote and transient manipulation of cellular activity with no need for

specialized equipment[9,10]. A recent study showed that metabolically derived clozapine arising from

systemic clozapine N-oxide (CNO) administration is indeed the *in vivo* actuator of DREADDs[9].

Clozapine binds with high affinity to many receptors and has side effects such as behavioural

inhibition and potentially fatal agranulocytosis[11]. Thus, the use of clozapine as a DREADD

actuator in humans may result in undesirable side effects[9]. Converted clozapine reaches its

maximal concentration at 2–3 hours after CNO treatment[12], indicating that the effects of CNO on

cellular activity are most likely to occur at this time point. These dynamic pharmacological profiles

of CNO *in vivo* result in a long and uncontrollable process due to irreversible drug effects and

metabolism, which limits the potential for emergency clinical applications such as seizure control[10].

Drosophila melanogaster odorant receptor 35a (OR35a) belongs to the seven-transmembrane

G-protein-coupled receptor superfamily and is a typical ligand-gated ion channel[13]; this channel

forms a complex with the odorant-binding subunit odorant receptor 83b (OR83b)[14-16]. 2-Pentanone

is the natural ligand of OR35a. In the present study, we co-expressed OR35a and OR83b in rodent

tissues by viral transduction. We demonstrated that *Drosophila* odorant receptors (DORs) were

activated by inhalation of 2-pentanone and effectively manipulated physiological processes and

rodent behaviour on a time scale of minutes, indicating excellent controllability of DORs in

practice. Here, we provide an easy-to-use, noninvasive, and spatiotemporally controllable

approach to manipulate physiological processes. Because of the safety, availability, and cost-

effectiveness of 2-pentanone, this "odourgenetic" approach has great potential for clinical

therapeutics.

2-Pentanone induces calcium influx in DOR-expressing cells

First, we describe our scheme for DOR cloning, design and activation by 2-pentanone and the

process through which physiological functions are manipulated by this system (Fig. 1a and b). To

verify whether 2-pentanone bound to and opened these DOR channels on mammalian cells, OR35a

and OR83b were expressed in a nonspecific manner in both *in vitro* and *in vivo* systems using a

plasmid with a Ubc promoter and an mCherry reporter (Extended Data Fig. 2a). A GCaMP-

expressing plasmid and a DOR-expressing plasmid were co-transfected into Neuro-2a cells (Fig.

1c and d) and HEK293T cells (Extended Data Fig. 2b). Calcium influx imaging experiments

indicated that bath application of 2-pentanone elicited robust calcium influx in DOR-expressing

Neuro-2a cells (Fig. 1c-f) and HEK293T cells (Extended Data Fig. 2b-f). A patch-clamp

experiment using Neuro-2a cells showed that bath application of 2-pentanone induced

depolarization of the membrane potential, indicating inward rectification by DORs (Fig. 1g and h).

These results indicated that DORs modulated intracellular calcium levels by inward rectification

and might therefore be useful for manipulating calcium-dependent cellular processes.

DOR activation elicits spikes in DOR-expressing neurons

To investigate whether DORs manipulated neuronal activity, lentiviruses (LVs) encoding DORs and adeno-associated viruses (AAVs) encoding GCaMP were injected to the S1 cortex of C57 mice. Because the length of the DOR sequence is approximately 3.5 kb, a lentivirus vector was chosen for DOR expression in the present study. Neuronal spikes were recorded under current-clamp conditions in cultured neurons and acute brain slices. The fluorescence response to calcium influx was examined by confocal microscopy in acute brain slices. The results showed that 2-pentanone induced robust neuronal spikes in DOR-expressing neurons in cell culture and acute brain slices (Fig. 2a-d). Bath application of 2-pentanone elicited a continuous fluorescence response in DOR-expressing neurons of acute brain slices (Fig. 2e-n and Supplementary Video 1). These results indicated that DORs enabled 2-pentanone-driven manipulation of neuronal activity *in vitro* and *in vivo*.

DORs enable fast on/off control of behaviour

For DOR expression under the control of the Cre-loxp system in the nervous system, an hSyn promoter following a loxp-stop-loxp sequence was inserted before the DOR sequence (Extended Data Fig. 2a). To determine whether DORs activated specific neurons, these receptors were expressed in GABAergic neurons in the S1 cortex of VGAT-Cre mice. Calcium influx imaging of brain slices was carried out to assess the fluorescence response of GABAergic neurons to 2-pentanone. The fluorescence response of brain slices showed that 2-pentanone activated the target DOR-expressing GABAergic neurons (Fig. 3a-c and Supplementary Video 4).

 Next, to determine whether 2-pentanone was delivered into the blood by inhalation and crossed

the blood–brain barrier into the cerebrospinal fluid (CSF), we examined the 2-pentanone

concentrations in the blood and CSF of mice exposed to this compound (2%, v/v) by LC–MS.

Plasma containing 2-pentanone and pure plasma were used as positive and negative controls,

respectively (Extended Data Fig. 1a-c). 2-Pentanone was detectable in both blood and CSF after a

short period of inhalation, indicating that this odorant was transported into the blood and then to

the CSF with this simple administration method (Fig. 3d, e and Extended Data Fig. 1d). Time-

course examinations were carried out to explore the dynamic profile of the 2-pentanone

concentration in the blood of mice and rats exposed to this compound. The 2-pentanone

concentration in the blood of both rats and mice showed a time-dependent increase during

inhalation of 2-pentanone and decreased rapidly after withdrawal of the odorant (Fig. 3f and

Extended Data Fig. 1e). These results indicated that 2-pentanone had the appropriate profile to be

a candidate manipulator of this DOR system.

The central nucleus of the amygdala (CeA) is a modular command system that exerts integrated

control of predatory hunting in mice[17], as we confirmed through an optogenetic experiment in the

present study (Supplementary Video 5) to ascertain whether DORs can control predatory hunting

behaviours by manipulating CeA neuronal activity. DORs were Cre-dependently expressed in

GABAergic neurons in the CeA, and predatory-like bites induced by inhalation of 2-pentanone

were observed. The behavioural experiment confirmed that 2-pentanone controlled rodent

behaviours by exogenously expressing DORs in target neurons in a non-invasive, fast on/off

manner (Fig. 3g-i and Supplementary Video 6).

DORs enable fast on/off manipulation of physiological processes

To verify whether DORs reversibly manipulated physiological processes in mice, a lentiviral

expressing DORs was injected into the pancreas, skeletal muscle and S1 cortex, respectively. 2-

Pentanone was administered to the mice by inhalation; their blood insulin content was then

examined using an ELISA, and their blood glucose was examined with a blood glucose meter.

Furthermore, the contraction of virus-injected muscles activated by 2-pentanone was observed

under a stereomicroscope, along with the associated limb movement. Neuronal activity was

examined by *in vivo* calcium influx imaging. A few minutes of 2-pentanone inhalation resulted in

a significant increase in the blood insulin concentration in pancreatic DOR-expressing mice and

therefore lowered the blood glucose level (Fig. 4a-c). Inhalation of 2-pentanone elicited muscle

contraction and limb movements within a few minutes, and the effect persisted until the odorant

was withdrawn (Fig. 4d-f). Calcium influx imaging in the S1 cortex in vivo showed that 2-

pentanone inhalation evoked robust continuous neuronal firing within a few minutes, which

persisted until 2-pentanone withdrawal (Extended Data Fig. 3a-d and Supplementary Video 2).

Repeated inhalation of 2-pentanone elicited another bout of neuronal firing. These results

confirmed that DORs enabled reversible manipulation of several physiological processes *in vivo*.

In the present study, DORs overcome many limitations of other methods, including the need for

expensive specialized equipment; the difficulty of delivering light to widely distributed cell

populations; the invasive procedures required to activate optogenetic systems in deep tissue; and

the long, slow pharmacodynamics and irreversible metabolic processes of the designer drugs used

in chemogenetics[6,9]. 2-Pentanone is a naturally produced phytochemical that is present in

bananas[18] and carrots[19]; this colourless liquid ketone has an acetone-like or intensely fruity odour.

It is sometimes used in very small amounts as a food additive to impart flavour. 2-Pentanone is

soluble in water and volatilizes rapidly to a gas at room temperature. Therefore, it was very easy

to administer by inhalation to manipulate our DOR system. Furthermore, the compound is

eliminated very quickly, mainly via exhalation, without a significant metabolic process. This

profile indicates the good controllability of systemic 2-pentanone levels in the present DOR system,

providing an easy-to-use tool that has potential for clinical applications in the treatment of various

diseases, such as diabetes, Parkinson's disease, and neocortical seizures[20].

References

1. Bernstein, J. G. & Boyden, E. S. Optogenetic tools for analyzing the neural circuits of

behavior. *Trends Cogn. Sci.* **15**, 592–600 (2011).

2. Arenkiel, B. R. et al. In vivo light-induced activation of neural circuitry in transgenic mice

expressing channelrhodopsin-2. *Neuron* **54**, 205–218 (2007).

3. Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale,

genetically targeted optical control of neural activity. *Nat. Neurosci.* **8**, 1263–1268 (2005).

4. Madisen, L. et al. A toolbox of Cre-dependent optogenetic transgenic mice for light-

induced activation and silencing. *Nat. Neurosci.* **15**, 793–802 (2012).

5. Carter, M. E. et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons.

Nat. Neurosci. **13**, 1526–1533 (2010).

6. Becnel, J. et al. DREADDs in *Drosophila*: a pharmacogenetic approach for controlling

behavior, neuronal signaling, and physiology in the fly. *Cell Rep.* **4**, 1049–1059 (2013).

7. Matveev, M. V. et al. Implantable devices for optogenetic studies and stimulation of

excitable tissue. *St. Petersbg. Polytech. Univ. J. Phys. Math.* **1**, 264–271 (2015).

8. Urban, D. J. & Roth, B. L. DREADDs (designer receptors exclusively activated by

designer drugs): chemogenetic tools with therapeutic utility. *Annu. Rev. Pharmacol.*

Toxicol. **55**, 399–417 (2015).

9. Gomez, J. L. et al. Chemogenetics revealed: DREADD occupancy and activation via

converted clozapine. *Science* **357**, 503–507 (2017).

10. Avaliani, N., Andersson, M., Runegaard, A. H., Woldbye, D. & Kokaia, M. DREADDs

suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.

Gene Ther. **23**, 760–766 (2016).

11.   Magnus, C. J. et al. Ultrapotent chemogenetics for research and potential clinical

180   applications. *Science* **364**, eaav5282 (2019).

181   12.   Raper, J. et al. Metabolism and distribution of clozapine-N-oxide: implications for

182   nonhuman primate chemogenetics. *ACS Chem. Neurosci.* **8**, 1570–1576 (2017).

183   13.   Krautwurst, D., Yau, K. W. & Reed, R. R. Identification of ligands for olfactory receptors

184   by functional expression of a receptor library. *Cell* **95**, 917–926 (1998).

185   14.   Larsson, M. C. et al. Or83b encodes a broadly expressed odorant receptor essential for

186   *Drosophila olfaction*. *Neuron* **43**, 703–714 (2004).

187   15.   DasGupta, S. & Waddell, S. Learned odor discrimination in *Drosophila* without

188   combinatorial odor maps in the antennal lobe. *Curr. Biol.* **18**, 1668–1674 (2008).

189   16.   Nichols, A. S. & Luetje, C. W. Transmembrane segment 3 of *Drosophila melanogaster*

190   odorant receptor subunit 85b contributes to ligand-receptor interactions. *J. Biol. Chem.* **285**,

191   11854–11862 (2010).

192   17.   Han, W. et al. Integrated control of predatory hunting by the central nucleus of the

193   amygdala. *Cell* **168**, 311–324.e18 (2017).

194   18.   McCarthy, A. I., Wyman, H. & Palmer, J. K. Gas chromatographic identification of banana

195   fruit volatiles. *J. Chromatogr. Sci.* **2**, 121–124 (1964).

196   19.   Lan, E. I., Dekishima, Y., Chuang, D. S. & Liao, J. C. Metabolic engineering of 2-

197   pentanone synthesis in *Escherichia coli*. *AIChE J.* **59**, 3167–3175 (2013).

198   20.   Kätzel, D., Nicholson, E., Schorge, S., Walker, M. C. & Kullmann, D. M. Chemical-genetic

199   attenuation of focal neocortical seizures. *Nat. Commun.* **5**, 3847 (2014).

Figure legends

Fig. 1. *Drosophila*-derived DORs control cellular activity

(**a**, **b**) Schematic drawing showing the principle of DOR design and their activation by 2-pentanone

to manipulate physiological functions. (**c**, **d**) Two frames (before and after application of 2-

pentanone) of time-lapse calcium influx images of GCaMP co-expressed with DORs or a control

in Neuro-2a cells. The fluorescence responses showed that 10 µM 2-pentanone evoked significant

calcium influx in DOR-expressing cells. (**e**, **f**) Time course of fluorescence responses from regions

of interest (ROIs), showing a robust calcium influx in DOR-expressing cells in response to 10 µM

2-pentanone. (**g**, **h**) Changes in the membrane potential change of current-clamped Neuro-2a cells;

bath application of 10 µM 2-pentanone significantly depolarized the membrane potential of DOR-

expressing cells (mean change $=16.38\pm7.79$ mV, n=25 cells).

Fig. 2. DORs enable 2-pentanone-driven neuronal spiking

(**a**, **c**) Voltage traces showing spikes in single current-clamped neurons of cultured cortical neurons and brain slices. Compared with the control, bath application of 10 μM 2-pentanone evoked robust firing spikes of DOR-expressing neurons in brain slices and cultured cortical neurons. (**b**, **d**) Spikes in current-clamped neurons in brain slices and cultured cortical neurons in response to application of 2-pentanone (slice: Control, 1.1±0.6 Hz, DORs, 6.9±3.1 Hz, p=0.000, n=36 neurons from nine mice; cultured neurons: Control, 0.8±0.5 Hz, DORs, 6.1±3.6 Hz, p=0.000, n=34 neurons from six cultures, non-parametric Mann–Whitney rank-sum test, two-sided). Experiments were repeated independently more than five times with similar results.

(**e, i**) Two frames (before and after application of 2-pentanone) of time-lapse calcium influx images of brain slices from C57 mice co-infected with AAV-GCaMP and LV-DOR or LV-control. Compared with the control, 10 μM 2-pentanone evoked significant calcium influx in DOR-expressing neurons. (**f**, **j**) Snapshots of fluorescence responses of control or DOR-expressing sample neurons (marked with white rectangles on left images) to 2-pentanone. (**g**, **k**) Time course of fluorescence responses to 2-pentanone in the above neurons. (**h**, **l**) Mean fluorescence intensity change ($\Delta F/F_0$) of DOR-expressing and control neurons in response to 2-pentanone (DORs: 1.56% ± 0.18%; control: 0.18% ± 0.02%, p=0.001, n = 25 neurons from eight mice). (**m, n**) Time course of fluorescence responses of control and DOR-expressing neurons in ROIs during application of 2-pentanone. Compared with the control, DOR-expressing neurons showed enhanced fluorescence responses to 10 μM 2-pentanone.

Fig. 3. DORs activate GABAergic neurons in the CeA and control predatory-like behaviours

(**a**)Time-lapse calcium influx images of brain slices from VGAT-Cre mice co-infected with AAV-GCaMP and LV-hSyn-LSL-DORs or a control virus; bath application of 10 μM 2-pentanone evoked significant calcium influx in DOR-expressing neurons. (**b**, **c**) Time course of fluorescence responses of control and DOR-expressing neurons in regions of interest (ROIs) during application of 2-pentanone. Compared with the control, DOR-expressing neurons showed enhanced fluorescence responses to 2-pentanone. (**d**, **e**) The concentration of 2-pentanone in the blood of mice was examined by LC–MS after inhalation of 2-pentanone (2%, v/v) for 3 min. 2-Pentanone was identified by the retention time (approximately 2.74 min) and the mass charge ratio (m/z= 87). (**f**) Dynamic concentration of 2-pentanone in the blood of rats exposed to this compound. The 2-pentanone concentration showed a rapid time-dependent increase within a few minutes after inhalation, and the concentrations remained elevated until withdrawal of the stimulus. Upon withdrawal of 2-pentanone, concentration decreased to approximately 20% of the peak concentration within 10 minutes (48.88±10.63 ng/ml to 12.11±3.76 ng/ml, n=4 for each time point). (**g**) Schematic of virus injection into the CeA and inhalation of 2-pentanone in freely moving mice. (**h**, **i**) Values reflecting predatory-like behaviours evoked by 2-pentanone. Compared with the control, both the number of bites and the total time spent biting were increased in DOR-expressing mice (n= 6, non-parametric Mann–Whitney rank-sum test, two-sided).

Fig. 4. DORs manipulate physiological functions *in vivo*

(**a**) Schematic of virus injection into the pancreas and inhalation of 2-pentanone in freely moving

mice. (**b**) Concentrations of insulin in the blood of mice after inhalation of 2-pentanone (control:

4.82±1.04 mIU/L; DORs: 9.32±3.34 mIU/L, p=0.001, n=27 mice, *t* test, two-sided) are shown. (**c**)

Time course of the blood glucose change in mice subjected to 2-pentanone inhalation. Compared

with the control, blood glucose began to decrease within a few minutes of 2-pentanone inhalation,

and this change persisted for more than 10 minutes after withdrawal of 2-pentanone. Data are

shown as the mean ± s.e.m. (n = 25, *p<0.05, repeated-measures ANOVA). (**d**) Schematic of virus

injection into muscles and inhalation of 2-pentanone using a mask. (**e**) The image shows a virus-

injected muscle marked by a green circle. (**f**) Vertical blue lines represent the muscle contraction

evoked by 2-pentanone. 2-Pentanone elicited continuous contraction of muscles expressing DORs.

Acknowledgements

This work was supported by the National Basic Research Program of China (81971060,32250018).

Author contributions

Y.Q.W designed and carried out behaviour test, analyzed data and wrote the paper; S.C.S carried

out electrophysiological and viral injection; X.Q.X carried out plasmid and viral construction and

cellular expressing; X.C.H designed and carried out 2-pentanone examination; W.L carried out 2-

pentanone examination; X.H.L carried out calcium imaging; L.H.W carried out blood insulin and

glucose test; W.T carried out muscle contraction experiments. Y.G carried out cells and neuron

culture; G.C designed the study and analyzed data; C.B.K designed the study, analyzed data and

wrote the paper.

Competing interests

Changbin Ke has filed patent applications whose value might be affected by this publication.

279